Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
9.41
+0.32 (3.52%)
Mar 20, 2026, 11:03 AM EDT - Market open
Rallybio Revenue
In the year 2025, Rallybio had annual revenue of $858.00K with 34.91% growth. Rallybio had revenue of $222.00K in the quarter ending December 31, 2025, with 484.21% growth.
Revenue (ttm)
$858.00K
Revenue Growth
+34.91%
P/S Ratio
56.04
Revenue / Employee
$57,200
Employees
15
Market Cap
49.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 858.00K | 222.00K | 34.91% |
| Dec 31, 2024 | 636.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRLYB News
- 17 days ago - Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
- 18 days ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
- 4 weeks ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 4 weeks ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 6 weeks ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 4 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 6 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire